September 26, 2024 09:01 PM EDT
Startups
Special

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

Drew Armstrong

Executive Editor

What makes a great biotech start­up?

Every year, the End­points 11 awards try to an­swer that ques­tion. We’ve spent the last sev­er­al months ex­am­in­ing dozens …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

Up­dat­ed: FDA ad­comm votes to lim­it Op­di­vo, Keytru­da use in stom­ach, esophageal can­cers based on key bio­mark­er

ARCH, biotech's star slug­ger, snags an­oth­er $3B for 13th fund

In­sil­i­co Med­i­cine, an ear­ly force in AI-dri­ven drug R&D, lets IPO plans pe­ter out for sec­ond year in a row

Flag­ship launch­es start­up to de­sign and make lipid nanopar­ti­cles for ge­net­ic med­i­cines

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times